UGA pharmacy researcher continues work on melanoma treatment

Mandi Murph

November 30, 2011

Print
Share    
Writer:
Sheila Roberson

Sheila Roberson

Public Relations Coordinator

Recent and archived articles by Sheila Roberson


College of Pharmacy
Work: 706-542-5303
Email:

Contact:
Mandi Murph

Mandi Murph

Assistant Professor

Pharmaceutical and Biomedical Sciences
College of Pharmacy
Work: 706/583-0216
Email:
,

Photography

  • magnify Mandi Murph

    Mandi Murph

Scroll Left 1 Scroll Right

Related Sites

Athens, Ga. - A research scientist in the University of Georgia College of Pharmacy is continuing her work on melanoma, a type of skin cancer that has become an emerging health crisis in the United States, with a grant from the American Cancer Society.

An associate professor of pharmaceutical and biomedical sciences, Mandi Murph and her colleagues have already demonstrated a significant reduction in cellular viability in vitro among melanoma cells treated with small-molecule inhibitors developed in their lab. The next step will be testing in vivo pharmacology and pharmacokinetics as a targeted therapeutic strategy against melanoma.

"This is a good time to be studying the disease," Murph said. "Significant outcomes mean more clinical trials using novel therapeutics and greater potential for treatment and survival."

Murph's research uses a two-pronged approach to test novel compounds to treat advanced melanoma and to study the signaling receptors that promote its survival. Her previous work supports the hypothesis that two molecular targets within the same signaling pathway represent potential molecular vulnerabilities that can be exploited in melanoma treatments.

"We believe that a significant reduction in the viability of advanced melanoma can be achieved by inhibiting metabolism in the lysophosphatic acid signaling network by targeting autotoxin, an enzyme known to generate LPA production," she said.

LPA3 receptors in the LPA pathway have been identified as playing a significant role in melanoma progression. Inhibition of LPA signaling through LPA3 receptors by identifying the structural requirements of the LPA3 receptors should help mediate melanoma cell survival, she said.

Incidences of melanoma and deaths occurring as a result of the cancer will likely continue to increase due to the aging Baby Boomer population and the higher probability for developing melanoma among those over the age of 70.

"The incidence of melanoma rose a staggering 619 percent from 1950 to 2000, coupled with an alarmingly low survival rate for advanced melanoma," Murph said. "In 2009 melanoma ranked sixth and seventh, respectively, in the estimated number of new cancer cases in men and women."

Murph's melanoma research is being funded by a four-year, $467,000 grant from the American Cancer Society. She also receives funding from the Georgia Cancer Coalition.

 

Filed under: Medical Science, Cancer

News Service

Director
Cynthia Hoke

706 / 542-8083
Public Relations Coordinator
Stephanie Schupska

706 / 542-6927
Public Relations Coordinator
Sara Freeland

706 / 542-8077
Science Writer
April Sorrow

706 / 542-7991

Broadcast, Video and Photography

Director
Steve Bell

706 / 542-8089
Broadcast Coordinator
Pete Konenkamp

706 / 542-8080
Photography
Rick O‘Quinn

706 / 542-8085